XML 28 R21.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value Measurements (Tables)
9 Months Ended
Nov. 01, 2025
Fair Value Disclosures [Abstract]  
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis

The following table presents financial instruments that are measured at fair value on a recurring basis at November 1, 2025, February 1, 2025 and November 2, 2024:

 

 

 

Fair Value Measurements

 

(In thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of November 1, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents - money market mutual funds

 

$

82,944

 

 

$

0

 

 

$

0

 

 

$

82,944

 

Marketable securities - mutual funds that fund
    deferred compensation

 

 

13,294

 

 

 

0

 

 

 

0

 

 

 

13,294

 

Total

 

$

96,238

 

 

$

0

 

 

$

0

 

 

$

96,238

 

As of February 1, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents - money market mutual funds

 

$

95,963

 

 

$

0

 

 

$

0

 

 

$

95,963

 

Marketable securities - mutual funds that fund
    deferred compensation

 

 

14,432

 

 

 

0

 

 

 

0

 

 

 

14,432

 

Total

 

$

110,395

 

 

$

0

 

 

$

0

 

 

$

110,395

 

As of November 2, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents - money market mutual funds

 

$

65,529

 

 

$

0

 

 

$

0

 

 

$

65,529

 

Marketable securities - mutual funds that fund
    deferred compensation

 

 

13,866

 

 

 

0

 

 

 

0

 

 

 

13,866

 

Total

 

$

79,395

 

 

$

0

 

 

$

0

 

 

$

79,395

 

Schedule of Liabilities Measure at Fair Value on Recurring Basis

The following table presents liabilities that are measured at fair value on a recurring basis at November 1, 2025, February 1, 2025 and November 2, 2024:

 

 

 

Fair Value Measurements

 

(In thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

As of November 1, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

$

0

 

 

$

0

 

 

$

412

 

 

$

412

 

Total

 

$

0

 

 

$

0

 

 

$

412

 

 

$

412

 

As of February 1, 2025

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

$

0

 

 

$

0

 

 

$

395

 

 

$

395

 

Total

 

$

0

 

 

$

0

 

 

$

395

 

 

$

395

 

As of November 2, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

$

0

 

 

$

0

 

 

$

3,793

 

 

$

3,793

 

Total

 

$

0

 

 

$

0

 

 

$

3,793

 

 

$

3,793

 

Schedule Of Deferred Compensation Plan Liabilities And Related Marketable Securities

The following tables present the balances and activity of the Company’s deferred compensation plan liabilities and related Marketable Securities:

 

(In thousands)

 

November 1, 2025

 

 

February 1, 2025

 

 

November 2, 2024

 

Deferred compensation plan current liabilities

 

$

2,072

 

 

$

4,259

 

 

$

193

 

Deferred compensation plan long-term liabilities

 

 

10,988

 

 

 

10,011

 

 

 

13,449

 

Total deferred compensation plan liabilities

 

$

13,060

 

 

$

14,270

 

 

$

13,642

 

Marketable securities - mutual funds that fund deferred compensation

 

$

13,294

 

 

$

14,432

 

 

$

13,866

 

 

(In thousands)

 

Thirteen
Weeks Ended
 November 1, 2025

 

 

Thirteen
Weeks Ended
 November 2, 2024

 

 

Thirty-nine
Weeks Ended
 November 1, 2025

 

 

Thirty-nine
Weeks Ended
 November 2, 2024

 

Deferred compensation liabilities

 

 

 

 

 

 

 

 

 

 

 

 

   Employer contributions, net

 

$

65

 

 

$

83

 

 

$

244

 

 

$

234

 

   Investment earnings

 

 

641

 

 

 

632

 

 

 

929

 

 

 

1,214

 

Marketable Securities

 

 

 

 

 

 

 

 

 

 

 

 

Mark-to-market gains (1)

 

 

(596

)

 

 

(585

)

 

 

(882

)

 

 

(1,169

)

Net deferred compensation expense

 

$

110

 

 

$

130

 

 

$

291

 

 

$

279

 

(1) Included in the mark-to-market activity related to equity securities still held at quarter-end, we recognized unrealized gains of $56,000 and $568,000 for the thirteen weeks ended November 1, 2025 and November 2, 2024, respectively, and unrealized gains of $865,000 and $1.1 million for the thirty-nine weeks ended November 1, 2025 and November 2, 2024, respectively.